Keyword: Trumenba

Back to college usually means meningitis vaccine marketing, and that's exactly what GlaxoSmithKline is doing.

A new meningitis B awareness drive from PatientPoint and Meningitis B Action Project puts materials in waiting rooms to spur vaccinations.

GlaxoSmithKline's moms against meningitis B are back on the air in TV ads promoting its Bexsero vaccine for back-to-college.

While you’re packing to leave for school, get vaccinated against meningitis B, GSK urges students in a new awareness push.

The Pfizer men B shot grabs an approval-speeding designation just two months after GSK's Bexsero—Trumenba's archrival—got the same boost.

Bexsero has been helping drive revenue growth for GSK, but now, with an EU approval, Pfizer’s Trumenba is set to challenge it in that lucrative market.

Even as Pfizer’s vaccine outfit suffers a painful Prevnar 13 slowdown around the world, the group may soon get a boost in Europe.

A top court in Ireland will hear claims brought by GlaxoSmithKline that Pfizer’s competing meningitis vaccine infringes on its Bexsero patents. For GSK, the suit follows a “fantastic” quarter for its fast-growing men B shot, an important growth cog acquired in its massive Novartis asset swap.

Right now, GlaxoSmithKline’s meningitis B vaccine, Bexsero, doesn’t have the key “universal use” endorsement the company wants from the CDC. So it’s spreading the word on its own.